Nabi Biopharmaceuticals begins human testing of novel vaccine to fight nicotine addiction

Rockville, Maryland, June 12, 2002 Nabi Biopharmaceuticals (Nasdaq: NABI) announced today that they have initiated NicVAX™ (Nicotine Conjugate Vaccine) phase I testing in humans. NicVAX is a proprietary and novel investigational vaccine designed to help the body develop antibodies that bind to nicotine and block it from reaching the brain. If shown to be safe and effective in subsequent clinical trials, NicVAX may help millions of people worldwide kick their addiction to cigarettes and tobacco products.

"NicVAX is an entirely new approach to fighting and preventing nicotine addiction," said David J. Gury, Nabi Biopharmaceuticals chairman, president and chief executive officer.

Of the 48 million adult U.S. smokers, about 70 percent, or nearly 34 million people have made at least one attempt to stop, yet only 1.2 million quit permanently, according to the U.S. Centers for Disease Control and Prevention.

"The reason quitting smoking is so difficult is because nicotine is highly addictive," according to Robert Naso, Ph.D., Nabi Biopharmaceuticals senior vice president of quality, regulatory and product development. "When a person smokes, nicotine enters the body and goes straight to the brain, where it generates positive sensations, such as pleasure and relaxation. However, the body does not develop antibodies against nicotine, no matter how much or for how long a person smokes. Based on earlier animal studies, NicVAX is a technology that enables the body to develop antibodies to nicotine. We believe that these antibodies, acting much like a sponge, will soak up the nicotine, preventing it from reaching the brain."

"By reducing the amount of nicotine available to stimulate the brain's pleasure centers, an immunized tobacco user would theoretically receive no positive reinforcement from nicotine use," according to Dr. Naso. In pre-clinical animal studies NicVAX generated antibodies that reduced nicotine levels in the brain by


Page: 1 2

Related biology news :

1. New hydrothermal vents discovered as South Pacific Odyssey research begins
2. DCI donor services begins distribution of tissue implants
3. Landmark, pivotal Phase IIb/III trial of biotoxin for cancer pain begins
4. Work begins on powering a sustainable future for the UK
5. As autumn approaches, this chickadees brain begins to expand
6. New study begins to unravel fate of toxic pollutants harbored in Arctic waters
7. UCSF begins distributing the first of its two embryonic stem cell lines
8. Acorda Therapeutics begins Phase 3 trials of Fampridine-SR for chronic spinal cord injury
9. The pathway to anxiety begins early in life
10. DOE begins international effort to sequence tree genome
11. Montana State University begins major trout and salmonid book collection

Post Your Comments:

(Date:10/10/2019)... British Columbia (PRWEB) , ... October 09, 2019 ... ... Sigma Anti-Bonding Calcium Symposium (ISACS) 2019 at Executive Plaza Hotel in Vancouver, Canada ... and share the knowledge of the various measures to develop healthy bone and ...
(Date:10/8/2019)... ... October 07, 2019 , ... Imaging data sets are generated ... optical projection tomography, optical coherence tomography, echocardiogram, light sheet microscopy, MRI and X-ray ... inhouse, a lot of research groups struggle with transforming these large and sometimes ...
(Date:10/3/2019)... ... October 01, 2019 , ... The CHEM+POUR Bag ... medias and to be a more environmentally sustainable evolution to plastic or glass ... experience and feedback from the original version we launched in September 2015,” said ...
Breaking Biology News(10 mins):
(Date:9/24/2019)... ... September 24, 2019 , ... Personalized ... training and site qualification for clinical trial sites and physician investigators. The ... potential clinical trial participants. , Clinical trial sites are currently located in San ...
(Date:9/24/2019)... (PRWEB) , ... September 24, 2019 , ... In the ... for research led by faculty at South Dakota School of Mines & Technology ... tiny microbes that attach to surfaces to form a slimy and yet strong layer ...
(Date:9/17/2019)... ... September 17, 2019 , ... Catalent, ... Project and Clinical Supplies Management, Asia Pacific (APAC) will present at the upcoming ... on Sept. 25-26, 2019. , On Thursday, Sept. 26, at 10:10 a.m., Ms. ...
(Date:9/17/2019)... ... September 17, 2019 , ... Geneticure, Inc., a Rochester ... today that the U.S. Patent and Trademark Office (USPTO) and European Patent Office ... class recommendations for hypertension treatment. , The patent applies to Geneticure’s first ...
Breaking Biology Technology:
Cached News: